[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-anterior-st-segment-elevation-myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-anterior-st-segment-elevation-myocardial-infarction":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100651448","prophylactic-iabp-in-delayed-presentation-anterior-stemi-100651448",false,"NCT07761455","Prophylactic IABP in Delayed-Presentation Anterior STEMI","Prophylactic Intra-Aortic Balloon Counterpulsation for Delayed-Presentation Anterior ST-Segment Elevation Myocardial Infarction: A Prospective, Multicenter, Randomized Controlled Trial (PROACTIVE-AMI)","PROACTIVE-AMI","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. First electrocardiogram on arrival shows ST-segment elevation ≥ 2 mm in at least two contiguous anterior leads, or sum of ST-segment elevation ≥ 4 mm in anterior leads.\n3. Ischemic symptoms (chest pain, chest tightness, upper abdominal discomfort, left shoulder radiation, etc.) onset to hospital arrival between ≥ 4 hours and ≤ 12 hours, and planned for primary PCI.\n4. Coronary angiography confirms the infarct-related artery is the proximal left anterior descending (LAD) (before the first septal branch or first diagonal branch) with TIMI flow grade 0 (total occlusion).\n5. Patient or legal representative provides written informed consent.\n\nExclusion Criteria:\n\n1. Established cardiogenic shock (systolic blood pressure \\\u003C 90 mmHg without inotropes\u002Fvasopressors, or requiring vasopressors to maintain systolic blood pressure ≥ 90 mmHg, AND blood lactate \\> 2.0 mmol\u002FL).\n2. Severe heart failure: Killip class ≥ III, or requiring non-invasive\u002Finvasive positive pressure ventilation before enrollment.\n3. Malignant arrhythmias, including cardiac arrest, ventricular fibrillation, ventricular flutter, pulseless ventricular tachycardia, or high-grade atrioventricular block.\n4. Severe mechanical complications (e.g., free wall rupture, ventricular septal defect, acute severe mitral regurgitation).\n5. Contraindications to IABP (severe peripheral vascular disease, aortic dissection, known aortic aneurysm, moderate-to-severe aortic regurgitation).\n6. Prior myocardial infarction or known chronic heart failure (left ventricular ejection fraction \\\u003C 50%).\n7. Prior coronary artery bypass grafting (CABG).\n8. Stroke within 1 month, or history of hemorrhagic stroke at any time.\n9. Active gastrointestinal bleeding within 3 months, or gastrointestinal diseases with increased bleeding risk.\n10. Received thrombolytic therapy for this episode.\n11. Initiation of any mechanical circulatory support (IABP, Impella, ECMO) before coronary angiography.\n12. Severe hepatic insufficiency (Child-Pugh C, or ALT \\>5×ULN with total bilirubin \\>3×ULN), renal insufficiency (eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m² or chronic dialysis), or end-stage disease with life expectancy \\\u003C 1 year.\n13. Pregnancy or lactation.\n14. Currently participating in another interventional trial.","ALL","18 Years",{"count":20,"type":21},504,"ESTIMATED","INTERVENTIONAL",[24],"NA","PROACTIVE-AMI is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication evaluating whether prophylactic intra-aortic balloon counterpulsation (IABP) initiated before primary percutaneous coronary intervention (PPCI) improves clinical outcomes in patients with delayed-presentation acute anterior ST-segment elevation myocardial infarction (STEMI). Eligible patients are adults aged ≥18 years who present 4 to 12 hours after symptom onset, have electrocardiographic evidence of anterior STEMI with proximal left anterior descending artery total occlusion (TIMI flow 0), and are planned for PPCI. Participants will be randomized 1:1 to pre-PPCI IABP plus standard PPCI or standard PPCI alone. The primary endpoint is 180-day major adverse cardiovascular events (MACE), defined as a composite of all-cause death, cardiogenic shock, and new or worsening heart failure. Secondary outcomes include individual MACE components, cardiac death, length of stay, NT-proBNP, left ventricular ejection fraction, and left ventricular end-diastolic volume. Safety outcomes include major bleeding, vascular complications, thrombocytopenia, and stroke.",[27],"Acute Anterior ST-Segment Elevation Myocardial Infarction",[29,30,31,32,33,34,35,36],"STEMI","Anterior myocardial infarction","Delayed presentation","Intra-aortic balloon pump","IABP","Primary PCI","Percutaneous coronary intervention","Mechanical circulatory support","NOT_YET_RECRUITING","2026-08-10",{"date":40,"type":41},"2026-08-12","ACTUAL",{"date":43,"type":21},"2026-08-01",{"date":45,"type":21},"2028-07-31",{"name":47,"class":48},"Qilu Hospital of Shandong University","OTHER",4,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100616482","phase-2-a-research-study-to-evaluate-the-efficacy-and-safety-of-sgc001-in-patients-with-anterior-wall-st-segment-elevation-myocardial-infarction-100616482","NCT07306182","A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction","A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of SGC001 Injection in Chinese Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction and Planned for Primary Percutaneous Coronary Intervention (pPCI)","Inclusion Criteria\n\n1.18-79 years of age (including boundary values), male or female;\n\n2.Anterior wall STEMI: (a) history of persistent chest pain\u002Fprecordial discomfort (\\>30 minutes); (b) upon admission, the ECG must meet the following requirements: i.For male participants \\>40 years old, ST-segment elevation ≥2 mm in leads V2 and V3; ii.For male participants ≤40 years old, ST-segment elevation ≥2.5 mm in leads V2 and V3; iii.For female participants, ST-segment elevation ≥1.5 mm in leads V2 and V3; If clinical symptoms of (a) are atypical, then (c) a positive point-of-care troponin test is required.\n\n3.Planned for pPCI treatment;\n\n4.Assessed as being able to complete dosing within 6 hours of the onset of persistent chest pain\u002Fprecordial discomfort symptoms;\n\n5.The participant or their legal guardian fully understands the objectives, nature, methods, and potential adverse reactions of the study, voluntarily agrees to participate, and has signed the informed consent form (ICF).\n\nExclusion Criteria\n\n1. History of the following cardiac conditions:\n\n   1. History of myocardial infarction, coronary revascularization (including percutaneous coronary intervention \\[PCI\\] and coronary artery bypass grafting \\[CABG\\], etc.);\n   2. History of cardiopulmonary resuscitation;\n   3. History of stroke within 6 months;\n   4. Presence of severe cardiac structural abnormalities such as aortic dissection, and ventricular aneurysm;\n2. Patients who have received thrombolysis;\n3. Patients with a life expectancy of less than 1 year;\n4. Febrile infection requiring systemic treatment within 2 weeks prior to screening;\n5. Concomitant left bundle branch block;\n6. Cardiogenic shock or hemodynamic instability;\n7. Concomitant severe arrhythmia (including high-degree atrioventricular block, sick sinus syndrome, sustained ventricular tachycardia, etc.) or implanted cardiac pacemaker;\n8. Definitive diagnosis of acute heart failure (Killip classification ≥ III; for details on Killip classification, see Appendix);\n9. Unable to undergo cardiac magnetic resonance (CMR) imaging according to the study protocol, or known allergy to any radiocontrast agent;","79 Years",{"count":59,"type":21},210,[61],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to standard clinical care in Chinese patients with acute anterior ST-segment elevation myocardial infarction (STEMI) who are planned for primary percutaneous coronary intervention (pPCI).",[27],[27,65],"ST-Segment Elevation Myocardial Infarction(STEMI)","RECRUITING","2026-07-10",{"date":69,"type":41},"2026-07-13",{"date":71,"type":41},"2026-03-09",{"date":73,"type":21},"2027-10",{"name":75,"class":76},"Beijing Sungen Biomedical Technology Co., Ltd","INDUSTRY",1,"Acute Anterior ST Segment Elevation Myocardial Infarction"]